Susan Zolla-Pazner

Summary

Affiliation: New York University
Country: USA

Publications

  1. ncbi request reprint A critical question for HIV vaccine development: which antibodies to induce?
    Susan Zolla-Pazner
    New York Veterans Affairs Harbor Healthcare System, New York, NY 10010, USA New York University School of Medicine, New York, NY 10016, USA
    Science 345:167-8. 2014
  2. pmc Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA
    Susan Zolla-Pazner
    Veterans Affairs Medical Center, New York, NY, USA
    J Virol 85:9887-98. 2011
  3. ncbi request reprint Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope
    Susan Zolla-Pazner
    New York Veterans Affairs Medical Center, New York, NY 10010, USA
    Virology 372:233-46. 2008
  4. pmc Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope
    Susan Zolla-Pazner
    New York University School of Medicine, 550 First Avenue, New York, NY, USA
    Virology 392:82-93. 2009
  5. pmc Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer
    Liuzhe Li
    Department of Pathology, New York University School of Medicine, New York, NY, USA
    Hum Antibodies 21:65-73. 2012
  6. pmc Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Mol Immunol 46:917-26. 2009
  7. doi request reprint Conserved structural elements in the V3 crown of HIV-1 gp120
    Xunqing Jiang
    Department of Biochemistry, New York University School of Medicine, New York, New York, USA
    Nat Struct Mol Biol 17:955-61. 2010
  8. pmc Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 6:e27780. 2011
  9. pmc The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York 10016, USA
    J Virol 78:2394-404. 2004
  10. pmc Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Virology 427:198-207. 2012

Research Grants

  1. Design and Use of HIV V3 Mimetic Immunogens
    Susan Zolla Pazner; Fiscal Year: 2004
  2. PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1
    Susan Zolla Pazner; Fiscal Year: 2005
  3. Design and Use of HIV V3 Mimetic Immunogens
    Susan Zolla Pazner; Fiscal Year: 2005
  4. PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1
    Susan Zolla Pazner; Fiscal Year: 2006
  5. Design and Use of HIV V3 Mimetic Immunogens
    Susan Zolla Pazner; Fiscal Year: 2006
  6. PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1
    Susan Zolla Pazner; Fiscal Year: 2007
  7. Design and Use of HIV V3 Mimetic Immunogens
    Susan Zolla Pazner; Fiscal Year: 2007
  8. Protective Human Monoclonal Antibodies to HIV-1
    Susan Zolla Pazner; Fiscal Year: 2009
  9. PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1
    Susan Zolla Pazner; Fiscal Year: 2004
  10. PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1
    Susan Zolla Pazner; Fiscal Year: 2003

Detail Information

Publications70

  1. ncbi request reprint A critical question for HIV vaccine development: which antibodies to induce?
    Susan Zolla-Pazner
    New York Veterans Affairs Harbor Healthcare System, New York, NY 10010, USA New York University School of Medicine, New York, NY 10016, USA
    Science 345:167-8. 2014
    ..In contrast, conventional HIV-1 antibodies have been induced by vaccination and correlated with reduced HIV-1 infection in a phase III vaccine trial. Here, I present evidence that both approaches should be pursued with equal vigor. ..
  2. pmc Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA
    Susan Zolla-Pazner
    Veterans Affairs Medical Center, New York, NY, USA
    J Virol 85:9887-98. 2011
    ....
  3. ncbi request reprint Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope
    Susan Zolla-Pazner
    New York Veterans Affairs Medical Center, New York, NY 10010, USA
    Virology 372:233-46. 2008
    ..Neutralizing activity was primarily due to V3-specific Abs. The results demonstrate that the immune response can be focused on a neutralizing epitope and show that the anti-V3 Abs induced recognize a diverse set of V3 loops...
  4. pmc Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope
    Susan Zolla-Pazner
    New York University School of Medicine, 550 First Avenue, New York, NY, USA
    Virology 392:82-93. 2009
    ..Greater than 80% of the neutralizing Abs were specific for V3, showing that the immune response could be focused on a neutralizing epitope and that vaccine-induced anti-V3 Abs have cross-clade neutralizing activity...
  5. pmc Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer
    Liuzhe Li
    Department of Pathology, New York University School of Medicine, New York, NY, USA
    Hum Antibodies 21:65-73. 2012
    ..One representative V3 mAb displayed very potent neutralizing activity to one of two viruses tested. This study shows the feasibility of utilizing a peptide tetramer to select epitope-specific B cells and produce mAbs...
  6. pmc Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Mol Immunol 46:917-26. 2009
    ..The preferential usage of selected Ig gene segments and the characteristic pattern of Ig gene usage by anti-V3 mAbs can be related to the conserved structure of the V3 region...
  7. doi request reprint Conserved structural elements in the V3 crown of HIV-1 gp120
    Xunqing Jiang
    Department of Biochemistry, New York University School of Medicine, New York, New York, USA
    Nat Struct Mol Biol 17:955-61. 2010
    ..As these regions are targeted by cross-clade neutralizing human antibodies, they provide a blueprint for the design of vaccine immunogens that could elicit broadly cross-reactive protective antibodies...
  8. pmc Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 6:e27780. 2011
    ..This will be useful information for designing vaccine immunogen inducing cross-neutralizing Abs...
  9. pmc The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York 10016, USA
    J Virol 78:2394-404. 2004
    ....
  10. pmc Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Virology 427:198-207. 2012
    ..The data suggest the presence of shared, conserved structural elements in the V2 loop, and these can be used in the design of vaccine immunogens inducing broadly reactive Abs with anti-viral activities...
  11. pmc Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies
    Timothy Cardozo
    New York University School of Medicine, Departments of Pharmacology, Pathology and Environmental Medicine, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 25:441-50. 2009
    ..More importantly, these calculations demonstrate that globally relevant, structurally conserved epitopes are present in the sequence variable V3 loop...
  12. pmc Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York 10016, USA
    J Virol 80:6865-72. 2006
    ....
  13. ncbi request reprint The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1
    Susan Zolla-Pazner
    Department of Pathology, New York University School of Medicine, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 20:1254-8. 2004
    ..These data illuminate the structural basis for both the breadth and specificity of a broadly neutralizing human mAb and contribute to our understanding of the epitopes recognized by Abs that protect against infection with HIV-1...
  14. ncbi request reprint Defining human immunodeficiency virus (HIV) type 1 immunotypes with six human monoclonal antibodies
    Arthur Nadas
    Institute of Environmental Medicine, New York University School of Medicine, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 20:55-65. 2004
    ....
  15. pmc Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, NY 10010, USA
    J Virol 79:5232-7. 2005
    ..The existence of such a unique MAb, which defines a complex epitope formed by a quaternary structure, suggests that there may be other new neutralizing HIV epitopes to target with vaccines...
  16. ncbi request reprint HIV infection in rural villages of Cameroon
    Phillipe Nyambi
    Department of Pathology, New York University School of Medicine, c o VA Medical Center, 423 E 23rd Street, Room 18124N, New York, NY 10010, USA
    J Acquir Immune Defic Syndr 31:506-13. 2002
    ..To evaluate HIV-1 antibody seroprevalence and risk factors for HIV seropositivity in rural areas of Cameroon...
  17. pmc Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins
    Tetsuya Kimura
    Department of Pathology, New York University School of Medicine, New York, NY 10010, USA
    Hum Antibodies 18:35-40. 2009
    ..The data provide further evidence for the existence of a unique quaternary epitope V2/V3 on the surface of unliganded virus...
  18. pmc Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects
    Evgeny Shmelkov
    Department of Pharmacology, New York University School of Medicine NYUSoM, New York, New York, United States of America
    PLoS ONE 6:e27279. 2011
    ....
  19. ncbi request reprint Genetic and biological properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: further evidence of broad HIV type 1 genetic diversity
    Ping Zhong
    Department of Pathology adn New York University School of Medicine, New York, New York 10010, USA
    AIDS Res Hum Retroviruses 19:1167-78. 2003
    ..This study further reveals the complexity of HIV-1 infection in rural Cameron and points to the future of the global epidemic, which may be characterized by more genetically diverse viruses...
  20. ncbi request reprint High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression
    Peter C Chien
    Department of Pathology, New York University School of Medicine, and Veterans Affairs New York Harbor Healthcare System, New York, New York, USA
    J Infect Dis 186:205-13. 2002
    ..These findings document a novel mechanism of HIV pathogenesis mediated by anti-gp120(CD4bd) Abs exhibiting suppressive activity on gp120 presentation...
  21. pmc Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop
    David Almond
    Department of Pharmacology, New York University School of Medicine NYUSoM, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 26:717-23. 2010
    ..From a structural point of view, there appears to be less diversity in this region of the HIV-1 "principle neutralizing domain" than previously appreciated...
  22. pmc Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
    Catarina E Hioe
    Department of Pathology, New York University Langone School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e10254. 2010
    ..Despite this evidence of V3 conservation, the ability of anti-V3 Abs to neutralize a significant proportion of HIV-1 isolates from different subtypes (clades) has remained controversial...
  23. pmc Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120
    Brett Spurrier
    Department of Biochemistry, NYU School of Medicine, New York, NY 10016, USA
    Structure 19:691-9. 2011
    ..Structural modeling suggests a way to understand the configuration of QNEs and the antigen-antibody interaction for QNE mAbs. Our data will be useful in designing immunogens that may elicit potent neutralizing QNE Abs...
  24. pmc Quantitative assessment of masking of neutralization epitopes in HIV-1
    Alpna Agarwal
    Department of Pharmacology, New York University School of Medicine, 550 First Avenue MSB 497, New York, NY 10016, USA
    Vaccine 29:6736-41. 2011
    ..These results have important implications for rational design of vaccines designed to induce neutralizing Abs by revealing epitopes that are minimally masked and maximally reactive with neutralizing Abs...
  25. pmc Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication
    Ekaterina Dadachova
    Albert Einstein College of Medicine, Bronx, New York, United States of America
    PLoS ONE 7:e31866. 2012
    ..Based on our earlier proof-of-principle results targeting HIV-1 infected cells with radiolabeled antibody (mAb) to gp41 viral antigen, we embarked on identifying a suitable candidate mAb for preclinical development...
  26. pmc Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV
    Brett Spurrier
    Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, New York, USA
    J Virol 88:4100-12. 2014
    ....
  27. pmc Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals
    Raiees Andrabi
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Virology 439:81-8. 2013
    ..These results suggest that clade C V3 is probably weakly immunogenic and that the V3 sequence of CRF02_AG viruses can serve as a plausible template for vaccine immunogen design...
  28. pmc Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens
    Valicia Burke
    Department of Biochemistry, New York University School of Medicine, New York, NY 10016, USA
    Structure 17:1538-46. 2009
    ....
  29. pmc Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes
    James Swetnam
    Department of Pharmacology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e15994. 2010
    ..Our results suggest one way to quantify and compare the magnitude of the conservation...
  30. pmc Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    J Virol 76:9035-45. 2002
    ..These studies demonstrate that human MAbs to conformation-sensitive epitopes of V3 display cross-clade reactivity in both binding to native, intact virions and neutralization of primary isolates...
  31. ncbi request reprint Thermodynamic signatures of the antigen binding site of mAb 447-52D targeting the third variable region of HIV-1 gp120
    April Killikelly
    Departments of Biochemistry and Molecular Pharmacology and Department of Pathology, New York University School of Medicine, New York, New York 10016, United States
    Biochemistry 52:6249-57. 2013
    ..Interrogation of the thermodynamic signatures of residues at the antigen binding interface gives key insights into their contributions in the antigen-antibody interaction. ..
  32. pmc Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject
    Liuzhe Li
    Department of Pathology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 7:e39534. 2012
    ....
  33. ncbi request reprint Infection with HIV type 1 group M non-B subtypes in individuals living in New York City
    Jacqueline M Achkar
    Department of Medicine, New York University School of Medicine, NY 10010, USA
    J Acquir Immune Defic Syndr 36:835-44. 2004
    ..To document infection with HIV type 1 (HIV-1) group M non-B subtypes in individuals living in New York City...
  34. pmc Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins
    Ekaterina Dadachova
    Albert Einstein College of Medicine, Bronx, New York, United States of America
    PLoS Med 3:e427. 2006
    ..The aim of this proof-of-principle study was to demonstrate the efficacy of a therapeutic strategy of targeting and eliminating HIV-1-infected cells with radiolabeled antibodies specific to viral proteins in vitro and in vivo...
  35. pmc Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial
    Susan Zolla-Pazner
    Research Service, Veterans Affairs Medical Center, New York, New York, United States of America
    PLoS ONE 8:e53629. 2013
    ....
  36. ncbi request reprint Improving on nature: focusing the immune response on the V3 loop
    Susan Zolla-Pazner
    Laboratory and Research Services, New York Veterans Affairs Medical Center and Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Hum Antibodies 14:69-72. 2005
    ..Current data, summarized here, support the hypothesis that the V3 region of gp120 can induce broadly-reactive, cross-neutralizing Abs and as such should constitute a prominent target of the immune response induced with an HIV vaccine...
  37. ncbi request reprint Structural basis for coreceptor selectivity by the HIV type 1 V3 loop
    Timothy Cardozo
    Department of Pharmacology and New York University School of Medicine, New York, NY 10016, USA
    AIDS Res Hum Retroviruses 23:415-26. 2007
    ..The results have additional implications for the design of HIV therapeutics, vaccines, and strategies for monitoring disease progression...
  38. pmc Immunoprophylaxis against mother-to-child transmission of HIV-1
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York, United States of America
    PLoS Med 3:e259. 2006
  39. pmc Distinct sequence patterns characterize the V3 region of HIV type 1 gp120 from subtypes A and C
    Klara Felsovalyi
    Department of Pharmacology, New York University School of Medicine and the New York Veterans Affairs Medical Center, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 22:703-8. 2006
    ..This lowest limit was 10(16). Although theoretically a p-value cannot be equal to 0.0, the p-value for the comparisons in question can be intuitively considered to be extremely small, or approximately 0.0.)...
  40. ncbi request reprint Evidence for CD4-enchanced signaling through the chemokine receptor CCR5
    Robert Staudinger
    Veterans Affairs New York Harbor Healthcare System, New York, New York 10016, USA
    J Biol Chem 278:10389-92. 2003
    ..Although the precise physiological role of the CD4 effects on CCR5-mediated signaling remains unknown, one can speculate that the cross-talk is a component of mechanisms involved in the fine tuning of immune system cell responses...
  41. pmc Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies
    David Almond
    Department of Pharmacology, New York University School of Medicine NYSoM, New York, NY 10016, USA
    Adv Virol 2012:803535. 2012
    ..As antibodies to a variable loop were recently identified as an inverse correlate of risk for HIV infection, the structure-function relationships discussed in this study may have relevance to HIV vaccine research...
  42. ncbi request reprint Identifying epitopes of HIV-1 that induce protective antibodies
    Susan Zolla-Pazner
    New York Veterans Affairs Medical Center and NYU School of Medicine, New York 10016, USA
    Nat Rev Immunol 4:199-210. 2004
  43. pmc Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2
    Luzia M Mayr
    Department of Pathology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 8:e70859. 2013
    ....
  44. pmc Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection
    Susan Zolla-Pazner
    Department of Veterans Affairs New York Harbor Healthcare System, New York, New York, United States of America New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 9:e87572. 2014
    ..The V1V2 antigens provide a link between RV144 and upcoming HIV-1 vaccine trials, and identify reagents and methods for evaluating V1V2 Abs as possible correlates of protection against HIV-1 infection...
  45. ncbi request reprint HIV type 1 group M clades infecting subjects from rural villages in equatorial rain forests of Cameroon
    Ping Zhong
    Department of Pathology, New York University School of Medicine, New York, NY, USA
    J Acquir Immune Defic Syndr 31:495-505. 2002
    ....
  46. ncbi request reprint Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity
    Michal Sharon
    Department of Structural Biology, The Weizmann Institute of Science, 76100, Rehovot, Israel
    Structure 11:225-36. 2003
    ..These data suggest that the 447-52D-bound V3(MN) and the 0.5beta-bound V3(IIIB) structures represent alternative V3 conformations responsible for selective interactions with CCR5 and CXCR4, respectively...
  47. pmc Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein
    Terri G Edwards
    Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Virol 76:2683-91. 2002
    ....
  48. ncbi request reprint Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization
    Osnat Rosen
    Department of Structural Biology, Weizmann Institute of Science, Rehovot 76100, Israel
    Biochemistry 44:7250-8. 2005
    ..5beta with variable residues underlie its strain specificity...
  49. pmc Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif
    Kenji Someya
    AIDS Research Center, National Institute of Infectious Diseases, Shinjuku ku, Tokyo 162 8640, Japan
    J Virol 79:1452-62. 2005
    ..These observations suggest that rBCG vectors have the potential to deliver an appropriate virus immunogen for desirable immune elicitations...
  50. pmc Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking
    Chavdar Krachmarov
    Public Health Research Institute, Laboratory of Retroviral Biology, 225 Warren St, Newark, NJ 07103 3535, USA
    J Virol 79:780-90. 2005
    ....
  51. pmc Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    James M Binley
    IMM2, Department of Immunology, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
    J Virol 78:13232-52. 2004
    ..As well as the significance for vaccine design, our data have implications for passive-immunization studies in countries where clade C viruses are common, given that only MAbs b12 and 4E10 were effective against viruses from this clade...
  52. pmc Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1
    Xinzhen Yang
    Dana Farber Cancer Institute, 44 Binney St, JFB 824, Boston, MA 02115, USA
    J Virol 78:12975-86. 2004
    ..These results underscore the qualitatively different humoral immune responses elicited during natural infection and after gp120 vaccination and help to explain the failure of gp120 as an effective vaccine...
  53. pmc A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response
    Peng Fei Zhang
    Department of Preventive Medicine and Biometrics, Biomedical Instrumentation Center, Uniformed Services University of the Health Sciences, Bethesda 20814, USA
    J Virol 76:644-55. 2002
    ..This is also the first primary HIV-1 isolate envelope glycoprotein found to be competent for CD4-independent infection...
  54. pmc The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection
    Abraham Pinter
    Laboratory of Retroviral Biology, Public Health Research Institute, 225 Warren Street, Newark, NJ 07103, USA
    J Virol 78:5205-15. 2004
    ..The rare antibodies capable of neutralizing a broad range of primary isolates thus appeared to be targeted to exceptional epitopes that are not sensitive to V1/V2 domain regulation of neutralization sensitivity...
  55. ncbi request reprint Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D
    Robyn L Stanfield
    Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Structure 12:193-204. 2004
    ..This novel mode of peptide-antibody recognition enables the antibody to bind to many different V3 sequences where only the GPxR core epitope is absolutely required...
  56. pmc Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates
    Hana Golding
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29A Room 1A21, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 76:6780-90. 2002
    ..They also indicate that six-helix bundles can form prior to fusion and that the lag time before fusion occurs may include the time needed to accumulate preformed six-helix bundles at the fusion site...
  57. pmc The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates
    Abraham Pinter
    Laboratory of Retroviral Biology, Public Health Research Institute, 225 Warren Street, Newark, NJ 07103 3535, USA
    J Virol 79:6909-17. 2005
    ....
  58. ncbi request reprint HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensi
    Mark K Louder
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, NIH, 40 Convent Drive, Bethesda, MD 20892, USA
    Virology 339:226-38. 2005
    ..Replication competent HIV-1 and isogenic envelope pseudoviruses have similar neutralization characteristics, but passage into PBMC is associated with decreased sensitivity to neutralization...
  59. doi request reprint Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination
    Victoria R Polonis
    Walter Reed Army Institute of Research, Washington, DC, USA
    Virology 375:315-20. 2008
    ....
  60. pmc Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection
    S Munir Alam
    Human Vaccine Institute, Box 3258, Duke University Medical Center, MSRBII Bldg, Room 4042, Durham, NC 27710, USA
    J Virol 82:115-25. 2008
    ....
  61. pmc Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, MD 20892, USA
    J Acquir Immune Defic Syndr 43:304-12. 2006
    ..Therefore, HIV-SELECTEST could be an important differential diagnostic tool for HIV vaccine trials, blood banks, and population screening worldwide...
  62. pmc Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses
    Xueling Wu
    Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA
    Virology 380:285-95. 2008
    ..These findings confirm that V3 antibodies recognize most primary viral strains, but that the epitope often has limited accessibility in the context of native envelope spike...
  63. pmc Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells
    Vincent Holl
    EA 3770, ULP, Institut de Virologie, 3 Rue Koeberle, F 67000 Strasbourg, France
    J Virol 80:6177-81. 2006
    ..We propose that, if such nonneutralizing inhibitory antibodies limit mucosal HIV transmission, they should be induced by vaccination...
  64. pmc Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity
    Robyn L Stanfield
    Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Virol 80:6093-105. 2006
    ....
  65. pmc Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation
    Vincent Holl
    Institut de Virologie, 3 Rue Koeberle, F 67000 Strasbourg, France
    Blood 107:4466-74. 2006
    ..We propose that IgG is able to efficiently inhibit HIV-1 replication in iMDDCs and should be one of the components to be induced by vaccination...
  66. ncbi request reprint A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs
    Aymeric de Parseval
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Biol Chem 280:39493-504. 2005
    ....
  67. ncbi request reprint Remembrance: G. Jeanette Thorbecke
    Vincent K Tsiagbe
    Autoimmunity 35:75-78. 2002
  68. ncbi request reprint Chronic lymphocytic leukemia with prostate infiltration mediated by specific clonal membrane-bound IgM
    Carol A Bogdan
    Medical Service, New York Harbor Healthcare System, New York 10010, USA
    Cancer Res 63:2067-71. 2003
    ....
  69. pmc Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set
    Amandeep K Dhillon
    Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
    Acta Crystallogr D Biol Crystallogr . 2008
    ....
  70. ncbi request reprint The antigenic determinants on HIV p24 for CD4+ T cell inhibiting antibodies as determined by limited proteolysis, chemical modification, and mass spectrometry
    Jason G Williams
    Laboratory of Structural Biology, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina 27709, USA
    J Am Soc Mass Spectrom 17:1560-9. 2006
    ..These results suggest that, possibly due to epitope competition, antibodies produced during HIV infection can negatively affect CD4+ T cell-mediated immunity against the virus...

Research Grants25

  1. Design and Use of HIV V3 Mimetic Immunogens
    Susan Zolla Pazner; Fiscal Year: 2004
    ..Finally, in Aim 3, we will examine how the intra- and inter-molecular interactions of gpl20 and gp41 affect neutralization sensitivity to anti-V3 mAbs. ..
  2. PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1
    Susan Zolla Pazner; Fiscal Year: 2005
    ..abstract_text> ..
  3. Design and Use of HIV V3 Mimetic Immunogens
    Susan Zolla Pazner; Fiscal Year: 2005
    ..Finally, in Aim 3, we will examine how the intra- and inter-molecular interactions of gpl20 and gp41 affect neutralization sensitivity to anti-V3 mAbs. ..
  4. PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1
    Susan Zolla Pazner; Fiscal Year: 2006
    ..abstract_text> ..
  5. Design and Use of HIV V3 Mimetic Immunogens
    Susan Zolla Pazner; Fiscal Year: 2006
    ..Finally, in Aim 3, we will examine how the intra- and inter-molecular interactions of gpl20 and gp41 affect neutralization sensitivity to anti-V3 mAbs. ..
  6. PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1
    Susan Zolla Pazner; Fiscal Year: 2007
    ..abstract_text> ..
  7. Design and Use of HIV V3 Mimetic Immunogens
    Susan Zolla Pazner; Fiscal Year: 2007
    ..Finally, in Aim 3, we will examine how the intra- and inter-molecular interactions of gpl20 and gp41 affect neutralization sensitivity to anti-V3 mAbs. ..
  8. Protective Human Monoclonal Antibodies to HIV-1
    Susan Zolla Pazner; Fiscal Year: 2009
    ..These antibodies could also be used to develop products to treat HIV infection when used in conjunction with anti-retroviral drugs. ..
  9. PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1
    Susan Zolla Pazner; Fiscal Year: 2004
    ..abstract_text> ..
  10. PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1
    Susan Zolla Pazner; Fiscal Year: 2003
    ..abstract_text> ..
  11. IMMUNOLOGIC RELATEDNESS AMONG AND BETWEEN HIV1 CLADES
    Susan Zolla Pazner; Fiscal Year: 2002
    ....
  12. IMMUNOLOGIC RELATEDNESS AMONG AND BETWEEN HIV1 CLADES
    Susan Zolla Pazner; Fiscal Year: 1999
    ....
  13. PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1
    Susan Zolla Pazner; Fiscal Year: 1999
    ..These experiments will establish correlations between the in vitro and in vivo efficacy of these mAbs. They will, as well, permit study of break-through infections and the course of infection when sterilizing immunity is not achieved. ..
  14. IMMUNOLOGIC RELATEDNESS AMONG AND BETWEEN HIV1 CLADES
    Susan Zolla Pazner; Fiscal Year: 2000
    ....
  15. PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1
    Susan Zolla Pazner; Fiscal Year: 2000
    ..These experiments will establish correlations between the in vitro and in vivo efficacy of these mAbs. They will, as well, permit study of break-through infections and the course of infection when sterilizing immunity is not achieved. ..
  16. IMMUNOLOGIC RELATEDNESS AMONG AND BETWEEN HIV1 CLADES
    Susan Zolla Pazner; Fiscal Year: 2001
    ....
  17. PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1
    Susan Zolla Pazner; Fiscal Year: 2001
    ..These experiments will establish correlations between the in vitro and in vivo efficacy of these mAbs. They will, as well, permit study of break-through infections and the course of infection when sterilizing immunity is not achieved. ..
  18. Protective Human Monoclonal Antibodies to HIV-1
    SUSAN B ZOLLA PAZNER; Fiscal Year: 2010
    ..These antibodies could also be used to develop products to treat HIV infection when used in conjunction with anti-retroviral drugs. ..